バージニアにおける脂肪肝の臨床試験
バージニア内の拠点で、脂肪肝に関する14件の研究が参加者を募集しています。
バージニア内の都市
公式研究テキスト（英語）
Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States
- Virginia Commonwealth University, Richmond
被験者募集中第2相
18歳〜75歳 · 全性別 · 2026/09/28更新 · NCT05832229A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition
- University of Virginia Medical Center, Charlottesville
- Richmond Veterans Administration Medical Center, Richmond
被験者募集中第2相
18歳〜75歳 · 全性別 · 2026/09/25更新 · NCT05519475A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
- Eximia Research - Norfolk, Norfolk
- Richmond Veterans Affairs Medical Center (Richmond VA Medical Center), Richmond
- Virginia Commonwealth University (VCU) Medical Center, Richmond
- 他1件
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07165028A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
- Akero Clinical Study Site, Norfolk
- Akero Clinical Study Site, Richmond
- Akero Clinical Study Site, Richmond
- 他3件
被験者募集中第3相
18歳〜80歳 · 全性別 · 2026/09/21更新 · NCT06528314A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
- GSK Investigational Site, Manassas
被験者募集中第3相
18歳〜75歳 · 全性別 · 2026/09/17更新 · NCT07221188A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)
- GI Alliance Richmond, Richmond
- GI Select Health Research, Richmond
被験者募集中第2相
18歳〜75歳 · 全性別 · 2026/09/09更新 · NCT07288138A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
- 89bio Clinical Study Site, Richmond
- 89bio Clinical Study Site, Richmond
- 89bio Clinical Study Site, Richmond
- 他1件
被験者募集中第3相
18歳〜80歳 · 全性別 · 2026/09/03更新 · NCT06318169A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
- 89bio Clinical Study Site, Richmond
- 89bio Clinical Study Site, Richmond
- 89bio Clinical Study Site, Richmond
被験者募集中第3相
18歳〜75歳 · 全性別 · 2026/09/03更新 · NCT06419374A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease
- GSK Investigational Site, Richmond
- GSK Investigational Site, Richmond
被験者募集中第2相
18歳〜70歳 · 全性別 · 2026/08/03更新 · NCT06613698A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
- GSK Investigational Site, Manassas
- GSK Investigational Site, Norfolk
被験者募集中第3相
18歳〜75歳 · 全性別 · 2026/07/27更新 · NCT07221227A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH
- GSK Investigational Site, Richmond
被験者募集中第2相
18歳〜75歳 · 全性別 · 2026/07/08更新 · NCT06920043Randomized Double Blinded Placebo-Controlled w/Semaglutide to Prevent Weight Gain After Liver Transplant
- Virginia Commonwealth University, Richmond
被験者募集中第2相
18歳〜75歳 · 全性別 · 2026/06/04更新 · NCT05424003Non-Invasive Quantification of Liver Health in NASH (N-QUAN)
- University of Virginia, Charlottesville
- Virginia Common wealth University, Richmond
被験者募集中
18歳〜75歳 · 全性別 · 2026/05/19更新 · NCT04054310Predicting Outcomes in Nonalcoholic Steatohepatitis With Advanced Fibrosis
- Virginia Commonwealth University, Richmond
被験者募集中観察研究
18歳以上 · 全性別 · 2026/04/02更新 · NCT05720663ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。